Multi omics analysis of mitophagy subtypes and integration of machine learning for predicting immunotherapy responses

Junzhi Liu1, Huimin Li2, Qiuping Dong2

  • 1Department of Otorhinolaryngology, Tianjin Medical University General Hospital, Tianjin 300052, China.

Aging
|June 24, 2024
PubMed

Insights

Mitophagy, a cell death process, impacts head and neck squamous cell carcinoma (HNSCC) progression and treatment. This study developed a risk score (MSRS) to predict HNSCC patient survival and immunotherapy response.

Area of Science:

  • Oncology
  • Cell Biology
  • Genomics

Background:

  • Mitophagy is crucial for tumor cell death but its role in head and neck squamous cell carcinoma (HNSCC) is unclear.
  • Effective HNSCC treatment is challenging, necessitating novel therapeutic targets.
  • Understanding mitophagy's impact on HNSCC outcomes and immunotherapy is vital.

Purpose of the Study:

  • To investigate the role of mitophagy in HNSCC.
  • To identify mitophagy-related subtypes and their prognostic significance.
  • To develop a predictive model for HNSCC patient survival and immunotherapy response.

Main Methods:

  • Pan-cancer analysis of mitophagy genes, unsupervised clustering for HNSCC subtypes, ssGSEA for pathway analysis, immune infiltration analysis.
  • Multi-omics data analysis for genomic variations, mutated gene pathways, and drug sensitivity.
  • Development and validation of a prognostic scoring model (MSRS) using machine learning and laboratory experiments.

Main Results:

  • Identified three distinct HNSCC subtypes based on mitophagy, with one subtype characterized as an 'immune desert'.
  • Developed the Mitophagy Subgroup Risk Score (MSRS) model to predict patient survival and response to immune checkpoint blockade therapy.
  • Validated the biological function of SLC26A9, a key gene in the MSRS model, through laboratory experiments.

Conclusions:

  • Mitophagy plays a significant role in HNSCC, influencing patient prognosis and immune evasion.
  • The MSRS model offers a novel tool for predicting outcomes and guiding immunotherapy in HNSCC patients.
  • This research provides new therapeutic strategies for HNSCC by targeting mitophagy pathways.